Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

Accurate diagnosis of diabetes mellitus and new paradigms of classification

Nature Reviews Endocrinology volume 14, pages 386–387 (2018)Cite this article

Subjects

A cluster analysis of five independent Swedish cohorts of people with diabetes mellitus has identified five clusters of classification based on age at diagnosis, BMI, HbA1c autoantibodies and markers of insulin resistance. Patients in each of the clusters have specific disease characteristics and unique risk profiles for complications from diabetes mellitus.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).

    Article  PubMed  Google Scholar 

  2. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 38, S8–S16 (2015).

    Article  Google Scholar 

  3. Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. Lancet. 389, 2239–2251 (2017).

    Article  PubMed  CAS  Google Scholar 

  4. Yang, Y. & Chan, L. Monogenic diabetes: what it teaches us on the common forms of type 1 and type 2 diabetes. Endocr. Rev. 37, 190–222 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Lim, S., Eckel, R. H. & Koh, K. K. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis 272, 33–40 (2018).

    Article  PubMed  CAS  Google Scholar 

  6. Lim, S., Kim, K. M. & Nauck, M. A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol. Metab. 2, 238–248 (2018).

    Article  CAS  Google Scholar 

  7. Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. International Diabetes Federation. IDF Diabetes Atlas - 8th Edition. IDF http://www.diabetesatlas.org/resources/2017-atlas.html (2017).

Download references

Acknowledgements

The authors acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care — East Midlands (NIHR CLAHRC — EM), the Leicester Clinical Trials Unit, and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Centre, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester.

Author information

Authors and Affiliations

  1. Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, Leicestershire, UK

    Sudesna Chatterjee & Melanie J. Davies

Authors
  1. Sudesna Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melanie J. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie J. Davies.

Ethics declarations

Competing interests

S.C. has received speaker fees or educational funding, or both, from Janssen, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim and grants in support of investigator-initiated trials from Boehringer Ingelheim and Janssen. M.J.D. reports personal fees from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International and grants from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Boehringer Ingelheim, and Janssen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chatterjee, S., Davies, M.J. Accurate diagnosis of diabetes mellitus and new paradigms of classification. Nat Rev Endocrinol 14, 386–387 (2018). https://doi.org/10.1038/s41574-018-0025-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-018-0025-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing